Intrahepatic and perihilar cholangiocarcinoma, in particular, grew faster in young patients than in older patients. The report affirms research from other Western countries suggesting such a trend.

Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...

Researchers at Karolinska Institutet in Sweden have analyzed and described in detail the immune cells residing in the human bile duct. The findings may pave the way for new treatment strategies ...

Patients with biliary tract cancer have altered genetic architecture in some immune system receptors. This has been shown by researchers at Karolinska Institutet in Sweden in a new study published in ...

ctDNA is a valuable prognostic biomarker for relapse in early-stage BTC, outperforming carbohydrate antigen 19-9 levels. ctDNA monitoring can detect molecular recurrence earlier than standard ...

Tovecimig combined with paclitaxel showed a 17.1% response rate in biliary tract cancer, outperforming paclitaxel alone. The COMPANION-002 study reported lower progressive disease rates with tovecimig ...

BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape Precision medicine has become a dominant theme in the treatment of biliary tract cancers (BTCs). Although prognosis ...

Biliary tract cancers, including intrahepatic, perihilar, and extrahepatic cholangiocarcinoma and gallbladder cancer, are among the most aggressive gastrointestinal malignancies. Treatment options ...

Biliary tract infection (BTI) is a disease with high morbidity and mortality, often associated with structural abnormalities such as common bile duct stones and malignant tumors. Although Pseudomonas ...

The Korean Association for Cancer Chemotherapy Research (KCSG) unveiled the achievements of domestic multi-center clinical ...